Pernas et al. have reported the analysis of intrinsic tumor subtypes and residual tumors following neoadjuvant trastuzumab-based chemotherapy in a group of 150 patients with stage II-IIIC HER2-positive breast cancers [90]. This evidence concerns the gene ERBB2 and neoplasm.